Gyre Therapeutics, Inc. (GYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.86+6.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GYRE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 116.4 | 116.6 | 105.8 | 113.5 | 102.3 | 7.3 | 20.9 | 0.0 | 0.0 | — | — | — | 0.3 | 3.6 | 57.9 | 97.6 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | 0.3 | 3.6 | 57.9 | 97.6 |
| Cost of Revenues | 6.8 | 5.4 | 3.9 | 4.6 | 4.8 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | 101.9 | 108.8 | 97.5 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | — | 13.7 | 12.0 | 13.8 | — | 68.9 | 53.0 | 43.9 | 21.5 | 12.8 | 11.6 | 6.0 | 5.3 | 6.6 | 49.1 | 95.2 |
| Operating Income | (12.3) | 11.5 | 16.2 | (67.2) | 9.2 | (87.9) | (57.4) | (57.3) | (33.8) | (21.8) | (20.4) | (13.8) | (7.5) | (10.1) | (8.1) | (9.7) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | 1.5 | 1.5 | 0.0 | 0.1 | 0.1 | 0.1 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.1 | 1.3 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (1.0) | (1.2) |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | — | — | — | 0.6 | 0.5 | 1.0 | 1.2 |
| EBT, Incl. Unusual Items | (12.3) | 14.4 | 23.2 | (77.0) | 9.4 | (87.9) | — | — | — | — | — | — | (29.1) | (46.7) | (7.1) | (8.5) |
| Income Tax Expense | 3.5 | 4.6 | 5.3 | 8.5 | 5.1 | — | — | — | — | — | — | — | 3.5 | 0.0 | (0.1) | 3.5 |
| Earnings from Continuing Operations | (15.7) | 9.9 | 17.9 | (85.5) | 4.3 | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | 1.8 | 4.9 | 5.8 | 7.5 | 2.0 | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | (17.0) | 9.9 | 17.9 | (85.5) | 4.3 | (87.9) | (56.2) | (55.2) | (30.1) | (21.6) | (16.9) | (14.8) | (6.6) | (10.0) | (7.0) | (8.5) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.17) | 0.06 | 0.14 | (1.41) | 0.04 | (2.87) | — | — | — | — | — | — | — | — | (0.21) | (0.27) |
| Diluted EPS | (0.17) | 0.02 | 0.05 | (1.41) | 0.03 | (2.87) | — | — | — | — | — | — | — | — | (0.21) | (0.27) |
| Revenue per Share | 1.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividend per Share | — | — | — | — | 0.24 | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 100.6 | 89.3 | 85.1 | 65.8 | 63.6 | 30.6 | — | — | — | — | — | — | — | — | 33.5 | 31.6 |
| Diluted Weighted Avg Shares | 100.6 | 103.2 | 102.3 | 65.8 | 75.7 | 30.6 | — | — | — | — | — | — | — | — | 33.5 | 31.6 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 14.0 | 17.7 | (66.2) | 10.3 | (87.6) | (57.2) | (57.1) | (33.7) | (21.6) | (20.0) | (13.3) | (6.8) | (9.1) | (5.9) | (7.3) |
| EBIT | (12.3) | 11.5 | 16.2 | (67.2) | 9.2 | (87.9) | (57.4) | (57.3) | (33.8) | (21.8) | (20.4) | (13.8) | (7.5) | (10.1) | (8.1) | (9.7) |
| Effective Tax Rate | -28.1% | — | — | -11.1% | 54.2% | — | — | — | — | — | — | — | -12.0% | -0.0% | 1.4% | -41.3% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.